Dupilumab Administration in an Adolescent with Severe Atopic Dermatitis Associated with BLAISE: Case Study
https://doi.org/10.15690/vsp.v25i1.3002
Abstract
Background. Blaschkolinear Acquired Inflammatory Skin Eruption (BLAISE) is a rare condition observed in variety of acquired benign diseases. There are no effective management approaches for patients with BLAISE.
Case description. Female patient, 17 years old. She suffers from atopic dermatitis from the age of 9. She was admitted to the dermatology department due to previous therapy inefficacy. The examination has revealed typical rashes along the Blashko lines along with atopic dermatitis signs. Considering severe and continuously recurrent course of the underlying disease, the patient was administered with interleukin (IL) 4/13 inhibitor dupilumab, 600 mg, followed by 300 mg once per 2 weeks. Both atopic dermatitis and BLAISE have regressed during this therapy.
Conclusion. Association of atopic dermatitis and BLAISE may demonstrate torpid course with topical and systemic glucocorticoids administration. Dupilumab, IL-4/13 inhibitor, may be an acceptable therapeutic option in patients with severe atopic dermatitis and comorbid BLAISE.
Keywords
Blaschko lines,
Blaschkolinear acquired inflammatory skin eruption,
BLAISE,
dupilumab,
atopic dermatitis,
children
Supporting agencies: Not specified
About the Authors
Vladislav V. Ivanchikov
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Not declared
Alexander I. Materikin
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Not declared
Anastasiya D. Alekseeva
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Not declared
Anastasiya A. Priymenko
Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Not declared
References
1. Kouzak SS, Mendes MST, Costa IMC. Cutaneous mosaicisms: concepts, patterns and classifications. An Bras Dermatol. 2013;88: 507–517. doi: https://doi.org/10.1590/abd1806-4841.20132015
2. Molho-Pessach V, Schaffer JV. Blaschko lines and other patterns of cutaneous mosaicism. Clin Dermatol. 2011;29(2):205–225. doi: https://doi.org/10.1016/j.clindermatol.2010.09.012
3. Ambarchyan ET, Kuzminova AD, Eldarova TK, et al. Ichthyosis Follicularis, Atrichia, and Photophobia (IFAP) Syndrome, Type 2: Clinical Case. Voprosy sovremennoi pediatrii — Current Pediatrics. 2024;23(3):181–187. (In Russ). doi: https://doi.org/10.15690/vsp.v23i3.2759
4. Darsha AK, Cohen PR. Blaschkolinear Acquired Inflammatory Skin Eruption (BLAISE): Case Report of a Young Man Whose Dermatosis had Features of Lichen Striatus and Blaschkitis. Cureus. 2020;12(10):e10785. doi: https://doi.org/10.7759/cureus.10785
5. Raposo I, Mota F, Fernandes IC, et al. Adult blaschkolinear acquired inflammatory skin eruption (BLAISE) with simultaneous features of lichen striatus and blaschkitis. Dermatol Online J. 2018;24(1):13030/qt6394z6nc.
6. Grosshans EM. Acquired blaschkolinear dermatoses. Am J Med Genet. 1999;85(4):334–337.
7. Aravind M, Do TT, Cha HC, et al. Blaschkolinear acquired inflammatory skin eruption, or blaschkitis, with features of lichen nitidus. JAAD Case Rep. 2016;2(2):102–104. doi: https://doi.org/10.1016/j.jdcr.2015.12.008
8. Baek YS, Seo JY, Seo SH, et al. Adult-onset lichen striatus versus adult blaschkitis: a clinicopathological review of 40 cases of acquired blaschkolinear inflammatory dermatosis. Eur J Dermatol. 2019;29(3):281–286. doi: https://doi.org/10.1684/ejd.2019.3556
9. Rovira-López R, Pujol RM. Blaschkolinear acquired inflammatory skin eruption (blaschkitis) following COVID-19 vaccination. JAAD Case Rep. 2022;26:35–37. doi: https://doi.org/10.1016/j.jdcr.2022.06.013
10. Bar-Ilan E, Mashiah J, Alkalay R, et al. Superimposed type 2 segmental atopic dermatitis: case series and review of the literature. Clin Exp Dermatol. 2022;47(9):1703–1706. doi: https://doi.org/10.1111/ced.15196
11. Kang HJ, Kim HJ, Han JH, et al. A Case of Linear Exacerbation of Atopic Dermatitis with Secondary Prurigo Nodularis. Ann Dermatol. 2022;34(4):297–300. doi: https://doi.org/10.5021/ad.20.072
12. Hladik F, Jurecka W, Hayek B, et al. Atopic dermatitis with increased severity along a line of Blaschko. J Am Acad Dermatol. 2005;53(5 Suppl 1):S221–S224. doi: https://doi.org/10.1016/j.jaad.2005.01.004
13. Atopicheskii dermatit: Clinical guidelines. Ministry of Health of the Russian Federation; 2024. 100 p. (In Russ). Доступно по: https://cr.minzdrav.gov.ru/view-cr/265_3. Ссылка активна на 24.12.2025.
Review
For citations:
Ivanchikov V.V., Materikin A.I., Alekseeva A.D., Priymenko A.A. Dupilumab Administration in an Adolescent with Severe Atopic Dermatitis Associated with BLAISE: Case Study. Current Pediatrics. 2026;25(1):23-27. (In Russ.) https://doi.org/10.15690/vsp.v25i1.3002
Views:
524
JATS XML
Email this article 
